Millennium Management
SGMT icon

Millennium Management’s Sagimet Biosciences SGMT Stock Holding History

Millennium Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.51M Buy
862,303
+275,356
+47% +$1.53M ﹤0.01% 3071
2025
Q4 		$3.47M Sell
586,947
-189,430
-24% -$1.36M ﹤0.01% 3409
2025
Q3 		$5.33M Buy
776,377
+700,737
+926% +$5.68M ﹤0.01% 3085
2025
Q2 		$576K Sell
75,640
-85,272
-53% -$360K ﹤0.01% 4810
2025
Q1 		$525K Sell
160,912
-532,335
-77% -$2.23M ﹤0.01% 4784
2024
Q4 		$3.12M Buy
693,247
+499,094
+257% +$2.53M ﹤0.01% 3267
2024
Q3 		$538K Sell
194,153
-382,596
-66% -$1.18M ﹤0.01% 4769
2024
Q2 		$1.97M Sell
576,749
-43,678
-7% -$200K ﹤0.01% 3546
2024
Q1 		$3.36M Buy
620,427
+572,376
+1,191% +$4.11M ﹤0.01% 3270
2023
Q4 		$260K Buy
48,051
+35,820
+293% +$169K ﹤0.01% 5035
2023
Q3 		$108K Buy
+12,231
New +$163K ﹤0.01% 5317

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management's SGMT Position: Q1 2026 in Review

Millennium Management increased its Sagimet Biosciences (SGMT) stake by 47% in Q1 2026, buying an estimated $1.53M and bringing the position to 862,303 shares worth $4.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Millennium Management first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.33M in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Millennium Management held 862,303 shares of Sagimet Biosciences worth $4.51M as of Q1 2026.
  • Millennium Management bought 275,356 Sagimet Biosciences shares in Q1 2026, an estimated $1.53M.
  • Sagimet Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3071 holding.
  • Millennium Management first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Millennium Management's Sagimet Biosciences position peaked at $5.33M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.